<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03588923</url>
  </required_header>
  <id_info>
    <org_study_id>SHC005-I-03</org_study_id>
    <nct_id>NCT03588923</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase I Study to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With Hepatitis C Virus (HCV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Sanhome Pharmaceutical, Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Sanhome Pharmaceutical, Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and
      antiviral activity of single and multiple ascending doses of SH229 in patients with chronic
      hepatitis C Virus infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 30 evaluable patients will be enrolled in this study. The planned dose levels are
      400, 600, and 800 mg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2018</start_date>
  <completion_date type="Actual">August 10, 2018</completion_date>
  <primary_completion_date type="Actual">August 10, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral effects of SH229, as measured by HCV RNA levels</measure>
    <time_frame>up to Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to peak plasma concentration(Tmax)</measure>
    <time_frame>up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration(Cmax)</measure>
    <time_frame>up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life time(t1/2)</measure>
    <time_frame>up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve(AUC)</measure>
    <time_frame>up to Day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SH229 (400 mg) or matching placebo, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SH229 (600 mg) or matching placebo, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SH229 (800 mg) or matching placebo, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SH229</intervention_name>
    <description>tablet, oral, 400 mg once daily for 3 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>tablet, oral, once daily for 3 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SH229</intervention_name>
    <description>tablet, oral, 600 mg once daily for 3 days</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>tablet, oral, once daily for 3 days</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SH229</intervention_name>
    <description>tablet, oral, 800 mg once daily for 3 days</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>tablet, oral, once daily for 3 days</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects are willing to voluntarily take effective contraceptive measures from
             screening to 6 months after the last dose;

          -  18-65 years of age;

          -  Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive, and a body weight ≥50
             kg for males and ≥45 kg for females;

          -  No previous treatment with any direct-acting antiviral (DAA) drugs for HCV, such as
             Boceprevir, Telaprevir, Simeprevir, Sofosbuvir, Daclatasvir, Asunaprevir;

          -  No antiviral treatment such as immune modulators, thymosin or other immune stimulating
             factors, interferon, or Chinese herbs in the past 6 months;

          -  HCV RNA ≥10*5 IU/mL at screening (Roche COBAS Taqman);

          -  Chronic genotype 1-6 HCV Infection;

          -  Serum ALT ≤10 times ULN;

          -  FibroScan score ≤17.5kPa within 6 months before screening or at screening, or absence
             of cirrhosis within 12 months before screening;

          -  Subjects are capable of understanding and complying with the protocol and have signed
             the informed consent form.

        Exclusion Criteria:

          -  Smoke more than 5 cigarettes per day within three months prior to screening;

          -  Subjects allergic to the study drug (including its excipients) or subjects who are
             prone to allergies;

          -  History of drug and/or alcohol abuse (alcohol consumption exceeding 14 units per week:
             1 unit = 285 mL of beer, or 25 mL of hard liquor, or 100 mL of wine);

          -  Blood donation or massive blood loss (&gt; 450 mL) within three months prior to
             screening;

          -  History of any non-HCV liver diseases, including but not limited to hemochromatosis,
             primary biliary cirrhosis, Wilson's disease, autoimmune hepatitis, drug or alcoholic
             hepatitis, non-alcoholic steatohepatitis, etc.;

          -  Subjects with dysphagia or with any gastrointestinal disorders (or postoperative
             conditions) that may affect the study drug absorption;

          -  Subjects with any diseases that increase the risk of bleeding, such as hemorrhoids,
             acute gastritis, or gastric and duodenal ulcers;

          -  Use of any drugs that alter liver enzyme activity within 28 days prior to screening;

          -  Use of any prescription drugs, over-the-counter drugs, vitamin products or herbal
             medicines within 14 days prior to screening;

          -  Use of special diet (including dragon fruit, mango, grapefruit, etc.), strenuous
             activities or other factors that may affect the disposition of the study drug within 2
             weeks prior to screening;

          -  Concomitant use of strong inhibitors or inducers of CYP3A4, P-gp or Bcrp, such as
             itraconazole, ketoconazole or dronedarone;

          -  Subjects with major changes in diet or exercise habits recently;

          -  Participation in other clinical trials within three months prior to enrollment;

          -  Electrocardiogram abnormalities with clinical significance;

          -  Laboratory tests with clinical significance or other clinical findings that indicate
             clinically significant diseases not associated with HCV infection (including but not
             limited to gastrointestinal, renal, hepatic, neurologic, hematological, endocrine,
             pulmonary, psychiatric, cardiovascular diseases);

          -  Pregnant or lactating women;

          -  Creatinine clearance ≤ 60 mL/min;

          -  Evidence of co-infection with HBV, HIV, or syphilis;

          -  Child-Pugh Grade B or C;

          -  Clinically significant hepatic decompensation including but not limited to, hepatic
             encephalopathy, hepatocellular carcinoma, variceal bleeding, ascites, etc.;

          -  Use of chocolate, food or beverages containing caffeine or xanthine within 24 hours
             prior to dosing;

          -  Use of products containing alcohol within 24 hours prior to dosing;

          -  Subjects with urine drug screening test positive, or with history of drug abuse in the
             past 5 years;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanhua Ding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phase I Clinical Trial Unit, The First Hospital of Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phase I Clinical Trial Unit, The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>August 24, 2018</last_update_submitted>
  <last_update_submitted_qc>August 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>NS5B</keyword>
  <keyword>SH229</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

